Imunon, Inc. (IMNN)
| Market Cap | 13.54M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.51M |
| Shares Out | 9.40M |
| EPS (ttm) | -2.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,785 |
| Open | 1.450 |
| Previous Close | 1.440 |
| Day's Range | 1.380 - 1.475 |
| 52-Week Range | 0.480 - 2.000 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+802.78%) |
| Earnings Date | May 9, 2024 |
About IMNN
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. It also develops ThermoDox, a direct chemotherapy. In addition, the company is developing IMNN-101, a COVID-19 booster vaccine which is in preclinical trials; IMNN-102 for the of the Lassa virus which is in preclinical t... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for IMNN stock is "Strong Buy" and the 12-month stock price forecast is $13.0.
News
IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in the second quarter
IMUNON Reports Compliance with Nasdaq Listing Requirements
LAWRENCEVILLE, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) (“IMUNON” or the “Company”), a clinical-stage drug-development company focused on developing DNA-mediated immuno-on...
IMUNON Reports 2023 Financial Results and Provides Business Update
Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J.
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-developm...
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vac...
IMUNON Files IND Application to Begin Human Testing of IMNN-101
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2 The application follows guidance provided to IMUNON in Pre-IND meeting with the FDA
IMUNON Announces Leadership Change
Executive Chairman to lead day-to-day operations, active search underway for CEO successor.Timing of upcoming milestones for key programs remains unchanged.
Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Trial will evaluate the effect of this combination therapy on minimal residual disease LAWRENCEVILLE, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-develop...
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
Data Show Strong Immunogenicity and Protection with IMUNON's PlaCCine DNA-Based Vaccine Modality LAWRENCEVILLE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage dr...
IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs in ovarian cancer and infectious diseases
IMUNON's VP of R&D to Present at the Vaccines Summit-2023
Dr. Jean Boyer to highlight updated data showing the advantages of IMUNON's PlaCCine modality and its applicability to multiple pathogens
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Multiple Near-Term Milestones
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc...
IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress
Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology...
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
“ A Tale of Two Pandemics: Lessons From the 1889 & 2019 Pandemics” presented by the Foreign Policy Association
IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
The MRD trial will evaluate the effect of this treatment combination on minimal residual disease. LAWRENCEVILLE, N.J.
IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON's FixPlas™ and Indiplas™ modalities in immuno-oncology.
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS and OS trend compared with control arm Continued follow...
IMUNON Releases Enterprise Video Highlighting the Company's Mission, Vision, Values, Breakthroughs and Technologies
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE, N.J., Sept. 26, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (N...
IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development LAWRENCEVILLE, N.J., Sept. 13, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN) , a cl...
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annu...
IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidate s in animal models
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON's FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a c...